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Summary
Background The WHO Director-General has issued a call for action to eliminate cervical cancer as a public health 
problem. To help inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical 
screening scenarios in low-income and lower-middle-income countries (LMICs) to examine the feasibility and timing 
of elimination at different thresholds, and to estimate the number of cervical cancer cases averted on the path to 
elimination.
Methods The WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), which consists of three independent 
transmission-dynamic models identified by WHO according to predefined criteria, projected reductions in cervical 
cancer incidence over time in 78 LMICs for three standardised base-case scenarios: girls-only vaccination; girls-only 
vaccination and once-lifetime screening; and girls-only vaccination and twice-lifetime screening. Girls were vaccinated at 
age 9 years (with a catch-up to age 14 years), assuming 90% coverage and 100% lifetime protection against HPV types 16, 
18, 31, 33, 45, 52, and 58. Cervical screening involved HPV testing once or twice per lifetime at ages 35 years and 45 years, 
with uptake increasing from 45% (2023) to 90% (2045 onwards). The elimination thresholds examined were an average 
age-standardised cervical cancer incidence of four or fewer cases per 100 000 women-years and ten or fewer cases per 
100 000 women-years, and an 85% or greater reduction in incidence. Sensitivity analyses were done, varying vaccination 
and screening strategies and assumptions. We summarised results using the median (range) of model predictions.
Findings Girls-only HPV vaccination was predicted to reduce the median age-standardised cervical cancer incidence 
in LMICs from 19·8 (range 19·4–19·8) to 2·1 (2·0–2·6) cases per 100 000 women-years over the next century 
(89·4% [86·2–90·1] reduction), and to avert 61·0 million (60·5–63·0) cases during this period. Adding twice-lifetime 
screening reduced the incidence to 0·7 (0·6–1·6) cases per 100 000 women-years (96·7% [91·3–96·7] reduction) and 
averted an extra 12·1 million (9·5–13·7) cases. Girls-only vaccination was predicted to result in elimination in 60% (58–65) 
of LMICs based on the threshold of four or fewer cases per 100 000 women-years, in 99% (89–100) of LMICs based on the 
threshold of ten or fewer cases per 100 000 women-years, and in 87% (37–99) of LMICs based on the 85% or greater 
reduction threshold. When adding twice-lifetime screening, 100% (71–100) of LMICs reached elimination for all three 
thresholds. In regions in which all countries can achieve cervical cancer elimination with girls-only vaccination, 
elimination could occur between 2059 and 2102, depending on the threshold and region. Introducing twice-lifetime 
screening accelerated elimination by 11–31 years. Long-term vaccine protection was required for elimination.
Interpretation Predictions were consistent across our three models and suggest that high HPV vaccination coverage 
of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake 
will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden.
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Introduction
Cervical cancer is the second most frequent cancer 
among women in low-income and lower-middle-income 
countries (LMICs).1 In 2018, 290 000 (51%) of the 570 000 
new cervical cancer cases worldwide occurred in women 
living in LMICs (500 000 [88%] when including upper-
middle-income countries).1 Without further intervention, 
these inequalities in the burden of cervical cancer are 
expected to grow, because recent increases in the uptake 
of human papillomavirus (HPV) vaccination and cervical 
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cancer screening have mainly occurred in high-income 
countries. Less than 30% of LMICs have introduced HPV 
vaccination compared with more than 85% of high-
income countries.2,3 Additionally, only about 20% of 
women in LMICs have ever been screened for cervical 
cancer compared with more than 60% in high-income 
countries.4,5
Inequalities in HPV vaccination and screening uptake 
persist, despite the large body of evidence demonstrating 
that these interventions are highly effective and cost-
effective. Large international randomised control clinical 
trials have shown that HPV vaccines are safe and highly 
effective against vaccine-type persistent infection and 
cervical precancerous lesions in women (with vaccine 
efficacy ≥93%).6–8 These vaccines target high-risk HPV 
types that cause about 70% (bivalent and quadrivalent 
vaccines: HPV types 16 and 18) and 90% (9-valent vaccine: 
HPV types 16, 18, 31, 33, 45, 52, and 58) of cervical 
cancers.9,10 Countries that have achieved high vaccination 
coverage have observed declines of 73–85% in vaccine-type 
HPV prevalence, and declines of 41–57% in high grade 
lesions (cervical intraepithelial neoplasia, grade 2 or worse) 
among young women, less than 10 years after imple-
mentation of HPV vaccination.11 The effectiveness of 
population-based cervical cancer screening has also been 
shown, through the sharp declines in age-standardised 
cervical cancer incidence in high-income countries fol-
lowing the implementation of cytology-based screening.12,13 
Randomised controlled trials have shown that HPV-
based tests are highly effective at detecting precancerous 
lesions and are likely to be more effective at preventing 
cervical cancer than visual inspection with acetic acid or 
Research in context
Evidence before this study
In May, 2018, WHO issued a global call to eliminate cervical 
cancer as a public health problem. To inform its global strategy 
to accelerate cervical cancer elimination, WHO created the 
Cervical Cancer Elimination Modelling Consortium (CCEMC) to 
examine the following key questions: what elimination 
threshold should be used; what prevention strategies can lead 
to elimination; when could elimination be reached for different 
countries; and how many cancers could be averted. The current 
working definition of elimination is an age-standardised 
cervical cancer incidence of four or fewer cases per 
100 000 women-years. Alternative definitions, such as an 
incidence of ten or fewer cases per 100 000 women-years and 
an 80–90% reduction in incidence, have also been suggested. 
The only previous multicountry modelling study of cervical 
cancer elimination suggests that global elimination is possible 
through girls-only human papillomavirus (HPV) vaccination at 
80–100% coverage with a perfectly effective 9-valent vaccine 
and twice-lifetime HPV-based screening. Given that models 
necessarily include simplifying assumptions, the goal of the 
consortium is to use multiple models, taking into account their 
respective strengths and limitations, to illustrate the robustness 
of predictions. A systematic comparative modelling approach 
was used. To form the CCEMC, WHO selected three models that 
met the predefined eligibility criteria: HPV-ADVISE, Harvard, 
and Policy1-Cervix. The models projected reductions in cervical 
cancer incidence over time based on standardised HPV 
vaccination and cervical screening scenarios determined after 
consultations at various WHO technical expert, advisory group, 
and global stakeholder meetings. Three elimination thresholds 
were examined (cervical cancer incidence of four or fewer cases 
per 100 000 women-years, ten or fewer cases per 
100 000 women-years, and ≥85% reduction in incidence).
Added value of this study
This comparative modelling analysis, which includes 
projections from three independent transmission-dynamic 
models, provides consistent results suggesting that 90% HPV 
vaccination coverage of girls can lead to cervical cancer 
elimination in most low-income and lower-middle-income 
countries (LMICs) within the next century. However, countries 
with the highest cervical cancer incidence (>25 cases per 
100 000 women-years) might not reach elimination at the 
threshold of four or fewer cases per 100 000 women-years by 
vaccination alone, although these countries are predicted to 
have the greatest absolute reductions. More than 90% of these 
LMICs are in sub-Saharan Africa. Screening would accelerate 
elimination by 11–31 years and will be necessary to eliminate 
cervical cancer in countries with the highest incidence. 
Profound health benefits are predicted on the path to 
elimination. Intensive scale-up of girls-only vaccination with 
twice-lifetime screening is predicted to halve the 
age-standardised cervical cancer incidence by 2048 (and by 
2061 with vaccination only), and to avert more than 74 million 
cervical cancer cases (61 million with vaccination only) in LMICs 
over the next century.
Implications of all the available evidence
The results of the CCEMC suggest that cervical cancer 
elimination as a public health problem is possible by the end of 
the century. However, to achieve elimination across all LMICs 
under the most ambitious threshold (four or fewer cases per 
100 000 women-years), both high HPV vaccination coverage 
and screening uptake will be necessary, which will require 
considerable international commitment. These results have 
directly informed WHO’s target of 90% HPV vaccination 
coverage, 70% screening coverage, and 90% of cervical lesions 
treated by 2030, as well as the WHO global strategy to 
accelerate cervical cancer elimination, which will be presented 
at the World Health Assembly in May, 2020.
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cytology.14–16 Finally, mathematical modelling studies have 
consistently shown that girls-only HPV vaccination and 
cervical cancer screen-and-treat pro grammes are cost-
effective in LMICs.17–22
Given the substantial global burden of cervical cancer, 
the increasing inequalities, and opportunities for 
effective and cost-effective primary and secondary 
prevention, the WHO Director-General made a global 
call in May, 2018, for action towards the elimination of 
cervical cancer as a public health problem.23 To achieve 
this goal, WHO is developing, with its partners, a global 
strategy towards the elimination of cervical cancer.24 
Fundamental questions that must be addressed in the 
global strategy include: what elimination definition 
and threshold should be used, what prevention strategies 
can lead to elimination, when could elimination be 
reached, how many cervical cancers and deaths can be 
averted on the path to elimination, and what are the most 
efficient and cost-effective strategies to reach elimination? 
These important questions can only be addressed 
through mathematical modelling, which integrates our 
understanding of HPV transmission, cervical carcino-
genesis, vaccine efficacy, and cervical screening and 
treatment performance to project the long-term health 
consequences of alternative cancer control policies. 
Hence, to inform its global strategy to accelerate cervical 
cancer elimination, WHO assembled the Cervical Cancer 
Elimination Modelling Consortium (CCEMC).25,26
In this Article, we describe the comparative modelling 
approach used by the CCEMC to inform WHO’s global 
strategy towards the elimination of cervical cancer,24 and 
present the CCEMC’s predictions of the impact of various 
HPV vaccination and screening elimination strategies 
on cervical cancer incidence in 78 LMICs. The specific 
objectives of this analysis were to identify prevention 
strategies that lead to elimination, estimate the timing of 
elimination, and predict the number of cervical cancer 
cases averted on the path to elimination, for different 
elimination thresholds and country characteristics. In 
an accompanying Article,27 we present the CCEMC’s 
predictions of the impact of HPV vaccination, screening, 
and treatment scale-up on cervical cancer mortality.
Methods
Comparative modelling approach
This comparative modelling analysis adhered to recently 
published guidelines for multi-model comparisons28 and 
for reporting model-based analyses of HPV vaccination 
and cervical screening29 (appendix pp 26–28). A three-step 
systematic comparative modelling approach was used.
The aim of the first step was to identify and select 
the mathematical models. To minimise selection bias, 
WHO selected models that met the following predefined 
eligibility criteria: the models explicitly included the 
dynamic transmission of HPV infection, were capable 
of projecting the impact of HPV vaccination and cer-
vical screening for all 78 LMICs, were independently 
developed and had been previously peer reviewed and 
published, and were able to provide predictions in a short 
timeframe to inform the WHO global strategy.24 Four 
independent models were identified: HPV-ADVISE,30,31 
Harvard,32,33 Policy1-Cervix,34–36 and Spectrum.37,38
The aim of the second step was to identify HPV 
vaccination and screening strategies that can lead to 
cervical cancer elimination and examine between-model 
variability. The four models were used to predict the 
change in cervical cancer incidence over time for 
40 standardised HPV vaccination and screening sce-
narios, with a subset of ten LMICs (appendix pp 14–15). 
Impact predictions were done without harmonising the 
basic structure of the models or parameters governing 
the setting and disease. The results were presented at 
various WHO technical expert, advisory group, and 
global stake holder meetings, and ultimately three HPV 
vaccination and screening scenarios were identified to 
proceed in a larger number of countries (78 LMICs).39 
The three final scenarios that were selected for the global 
analysis (see scenario descriptions below and in the 
appendix p 16) were chosen as they showed potential for 
cervical cancer elimination in LMICs and follow WHO 
recommen dations for HPV vaccination and cervical 
screening.40,41
Finally, the aim of the third step was to produce 
predictions of the population-level impact of the three 
HPV vaccination and cervical screening scenarios for all 
78 LMICs. Three of the four models (HPV-ADVISE, 
Harvard, and Policy1-Cervix) were able to provide predic-
tions for all 78 LMICs within the required timelines, and 
thus form the core models of the CCEMC. The structure 
of the models and the comparative modelling approach 
were presented and reviewed by the WHO Advisory 
Committee on Immunization and Vaccines related 
Research (IVIR).39
Model description
The three CCEMC models (HPV-ADVISE, Harvard, and 
Policy1-Cervix) have been used extensively to inform 
recommendations on cervical screening and HPV 
vaccination in Australia, Canada, the UK, the USA, and 
at a global level.30–36 Although developed independently, 
the models have common features. First, they are 
transmission-dynamic models of HPV infection and the 
natural history of cervical cancer. Second, they include 
the following components: sexual behaviour and HPV 
transmission, natural history of cervical cancer, vacci-
nation, and screening, diagnosis, management, and 
treatment of cervical lesions and cancer. HPV transmission 
and cervical carcinogenesis are modelled for the HPV 
types in the 9-valent vaccine (HPV types 16, 18, 31, 33, 45, 
52, 58) and other high-risk types. The models simulate 
type-specific HPV transmission through sexual activity, 
based on different risk groups and sexual mixing. The 
models reproduce the type-specific natural history of 
cervical cancer, from persistent HPV infection to cervical 
See Online for appendix
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cancer via precancerous cervical lesions (cervical 
intraepithelial neoplasia grade 1 to 3). All models assume 
that HPV vaccines are prophylactic and capture post-
vaccination herd effects. They can also simulate complex 
cervical screening and treatment algorithms at the 
individual level, by tracking and simulating each woman’s 
screening history. Finally, all models were calibrated to 
highly stratified sexual behaviour and epidemiological 
data, validated to clinical trials or post-vaccination data, 
or both, and reproduce the age-specific cervical cancer 
incidence estimates from the Global Cancer Observatory 
(GLOBOCAN) 2018 for all 78 LMICs42 (see the appendix 
pp 18–23 for further details of the CCEMC models).
Vaccination and screening scenarios
Three standardised base-case HPV vaccination and 
cervical screening scenarios were examined. The first 
was vaccination only: routine vaccination of girls aged 
9 years (with a 1-year multi-age cohort catch-up to age 
14 years) reaching 90% coverage in the first year (2020). 
The second was vaccination and once-lifetime screening: 
scenario 1 plus one lifetime screen at age 35 years, 
assuming screening uptake ramp-up over time (45% in 
2023, 70% in 2030, and 90% in 2045). The third was 
vaccination and twice-lifetime screening: scenario 1 plus 
two lifetime screens at ages 35 years and 45 years, 
assuming screening uptake ramp-up over time (45% in 
2023, 70% in 2030, and 90% in 2045).
For the base-case scenarios, HPV vaccination was 
assumed to provide 100% efficacy against HPV types 16, 
18, 31, 33, 45, 52, and 58, and lifelong duration of 
protection. Cervical screening was assumed to involve 
primary HPV screen-and-treat testing, with 100% pre-
cancer treatment efficacy and 10% of individuals lost to 
follow-up (due to treatment non-compliance). To estimate 
the population-level impact of the base-case scenarios, we 
also modelled a status quo scenario, which assumes no 
further scale-up of preventive interventions (see appendix 
p 16 for more details). The 40 HPV vaccination and 
cervical screening scenarios from step 2 of the comparative 
modelling approach were used to understand the impact 
of model assumptions on predictions. The sensitivity 
analysis included varying HPV vaccination coverage, 
the targeted population (girls only vs girls and boys), ages 
at vac cination, screening frequency, the HPV types 
targeted by the vaccine, and the duration of vaccine 
protection. Results of the sensitivity analysis are shown 
for two example countries, representing one low-income 
country in sub-Saharan Africa (Uganda) and one lower-
middle-income country in east Asia (Vietnam).
Outcomes
Population-level impact was measured with three main 
outcomes: age-standardised cervical cancer incidence, 
relative reductions in age-standardised cervical cancer 
incidence (vs status quo), and number of cases averted 
(vs status quo). The time horizon of the analysis was 
from 2020 to 2120. The age-standardised cervical cancer 
incidence and relative reductions in incidence over time 
were used to assess the feasibility and timing of cervical 
cancer elimination at different thresholds. We used the 
CCEMC models to independently estimate the outcomes 
for each of the 78 countries. Results were also aggregated 
by World Bank income level and region (see appendix 
p 17 for a description of country characteristics). Out-
comes are presented with the median (range) of the 
predictions of the three models to represent between-
model uncertainty.28
The age-standardised cervical cancer incidence over 
time was estimated for each CCEMC model, vaccination, 
and screening scenario, and for each country using the 
predictions of age-specific cervical cancer incidence over 
time and applying the age structure of the 2015 global 
female population aged 0–99 years.43 Reductions (absolute 
Figure 1: Dynamics of cervical cancer incidence after HPV vaccination and 
cervical screening
Average age-standardised cervical cancer incidence per 100 000 women-years 
(A) and relative reduction in incidence (B) after HPV vaccination and screening 
ramp-up in low-income and lower-middle-income countries. Median prediction 
from the three models. Vaccination coverage=90% at age 9 years (and at ages 
10–14 years in 2020). Vaccine efficacy=100% against HPV16, 18, 31, 33, 45, 52, 
and 58. Vaccine duration=lifetime. Screening=HPV testing. Screening 
uptake=45% (2023–29), 70% (2030–44), and 90% (2045 onwards). Screen and 
treat efficacy=100%. Loss to follow-up=10%. Equilibrium occurs 90–100 years 
after the introduction of HPV vaccination only (and earlier for the screening 
scenarios). HPV=human papillomavirus.
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and relative) in age-standardised cervical cancer incidence 
over time were estimated compared to the status quo. 
Finally, the cumulative number of cases averted over time 
was estimated with a three-step process. First, for each 
CCEMC model, vaccination, and screening scenario, and 
country, we estimated the number of cervical cancers by 
year and age group by multiplying the predicted age-
specific cervical cancer incidence and the age-specific UN 
population growth projections.43 Second, we estimated 
the number of cervical cancers in each year by summing 
the cases predicted in each age group. Third, the number 
of cases averted in each year was estimated by subtracting 
the number of cases predicted under each vaccination 
and screening scenario from those predicted under the 
status quo. The number of cancer cases averted in 
each World Bank income level or region was estimated 
by aggregating the country-specific results. The model 
predictions were done independently by each group 
and collated by the study’s coordinating centre (Laval 
University, Québec, QC, Canada). See the appendix 
(pp 18–25) for more methodological details.
Elimination thresholds
Our base-case definition of elimination is an age-
standardised (2015 world standard) cervical cancer 
incidence of four or fewer cases per 100 000 women-years, 
which is the current working definition used by WHO 
and the proposed WHO global strategy towards 
elimination of cervical cancer.24 The threshold was 
determined following multiple WHO technical expert 
meetings and global stakeholder consultations held 
between March and September, 2018.24 Alternative 
definitions, such as a higher incidence threshold (ten 
cases per 100 000 women-years) and a percentage 
reduction in incidence (85–90%), were also discussed.39 
Thus, as a sensitivity analysis, two alternative definitions 
were explored: age-standardised cervical cancer incidence 
of ten or fewer cases per 100 000 women-years and a 
reduction in age-standardised cervical cancer incidence of 
≥85% (vs status quo). Elimination was predicted to occur 
the first year in which a country reached the threshold 
definition. Elimination within a region or income level 
was predicted to occur the year in which all countries 
within the region or income level reached elimination.
Role of the funding source
This study was partly funded by WHO. WHO contributed 
to study design, data analysis, data interpretation, and 
writing of the report. The other funding sources had no 
role in this work. MB, JJK, and KC had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
The CCEMC models predicted that girls-only HPV 
vaccination with 90% coverage will reduce the median 
age-standardised cervical cancer incidence in LMICs from 
19·8 (range 19·4–19·8) to 2·1 (2·0–2·6) cases per 
100 000 women-years over the next century, which 
represents an 89·4% (86·2–90·1) reduction in cervical 
cancer (vs the status quo; figure 1, table). The addition of 
screening was predicted to substantially accelerate 
declines in cervical cancer and to lead to lower cervical 
cancer incidence at equilibrium. HPV vaccination and 
once-lifetime screening was predicted to reduce the 
average age-standardised cervical cancer incidence in 
LMICs to 1·0 (0·9–2·0) cases per 100 000 women-years 
over the next century (95·0% [89·0–95·3] reduction), 
whereas HPV vaccination and twice-lifetime screening 
was predicted to reduce the average age-standardised 
cervical cancer incidence to 0·7 (0·6–1·6) cases per 
100 000 women-years at equilibrium (96·7% [91·3–96·7] 
reduction). Additionally, the models predicted that cervical 
cancer incidence will be halved in LMICs by 2061 (2060–63) 
with HPV vaccination alone, by 2055 (2055–56) when 
adding once-lifetime screening, and by 2048 (2047–49) 
when adding twice-lifetime screening. Notably, the 
models predicted that HPV vaccination with or without 
screening will reduce age-standardised cervical cancer 
incidence in women of childbearing age (<45 years) by 
more than 85% before 2050 (appendix p 5).
The predicted dynamics of cervical cancer incidence 
following HPV vaccination only, and for HPV vaccination 
with once-lifetime or twice-lifetime screening, were very 
similar for the three models (figure 2). Additionally, 
although the age-standardised cervical cancer incidence 
in 2020 varied widely by country income level and region 
(figure 2; appendix p 5), the models predicted that the 
post-intervention dynamics and percentage reduction in 
cervical cancer incidence will be similar (figure 2, table). 
For example, the predicted percentage reduction in 
cervical cancer following HPV vaccination only varied 
from 87% (range 84–88) in sub-Saharan Africa to 
91% (88–93) in South Asia, and percentage reductions 
following HPV vaccination with twice-lifetime screening 
varied from 96% (90–96) in sub-Saharan Africa to 
97% (93–97) in South Asia. However, the models predicted 
that age-standardised cervical cancer incidence following 
HPV vaccination with or without screening will vary 
greatly between regions and countries because of the 
large heterogeneity in the starting incidence (figure 2, 
table), which contributed to variability between countries 
in the potential for and timing of elimination.
With the base-case elimination threshold (four or fewer 
cases per 100 000 women-years), the CCEMC models 
predicted that girls-only HPV vaccination could lead to 
cervical cancer elimination in 60% (range 58–65) of 
LMICs, HPV vaccination with once-lifetime screening 
could lead to elimination in 96% (60–97) of LMICs, and 
HPV vaccination with twice-lifetime screening could 
lead to elimination in 100% (71–100) of LMICs (figure 3, 
table). HPV vaccination alone was predicted to result 
in elimination in all regions in the world, except 
for sub-Saharan Africa, where 27% (range 24–37) of 
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countries would reach elimination, and Latin America 
and Caribbean, where 80% (80–80) of countries would 
reach elimination. The countries that were not predicted 
to reach elimination through HPV vaccination alone 
were those with an age-standardised cervical cancer 
incidence of more than 25 cases per 100 000 women-
years in 2020 (figure 4, appendix p 7). These same 
countries were predicted to have the greatest absolute 
reductions in cervical cancer incidence following HPV 
vaccination (figure 4). Importantly, for these countries, 
mainly in sub-Saharan Africa, once-lifetime or twice-
lifetime screening was required to achieve elimination. 
Country-specific and model-specific predictions of elimi-
nation and the age-specific cervical cancer incidence at 
equilibrium are shown in the appendix (p 7).
The models predicted that among the regions that 
can achieve elimination (four or fewer cases per 
100 000 women-years) with girls-only HPV vaccination 
alone, elimination will occur between 2074 and 2102 
(table). Adding twice-lifetime screening was predicted to 
accelerate elimination by 11–31 years. In sub-Saharan 
Africa, where both HPV vaccination and twice-lifetime 
screening are required to achieve elimination, elimi-
nation is predicted to occur slightly before 2100 (table). 
Country-specific and model-specific predictions of the 
year of elimination are provided in the appendix (p 8).
The CCEMC models predicted that girls-only HPV 
vaccination could lead to cervical cancer elimination 
in 99% (range 89–100) of LMICs based on a threshold 
of ten or fewer cases per 100 000 women-years, and in 
87% (37–99) of LMICs based on a threshold of an 85% or 
greater reduction (table; figure 3; figure 4). Adding once 
or twice-lifetime screening was predicted to result in 
cervical cancer elimination for 100% of LMICs under 
both thresholds. Elimination was also predicted to occur 
faster with these thresholds (table).
The CCEMC models predicted that 21·3 million 
(range 20·7–21·3) cervical cancer cases will occur in 
LMICs between 2020 and 2060 without further inter-
ventions (status quo). During the same period, including 
girls-only HPV vaccination with 90% coverage was 
predicted to avert 3·2 million (3·0–3·6) cervical cancer 
cases; adding once-lifetime screening to vaccination 
was predicted to avert an extra 2·2 million (1·8–2·7) 
cases, and adding twice-lifetime screening was predicted 
to avert an extra 4·6 million (3·9–4·8) cancer cases 
(figure 5; appendix pp 2–4). Hence, in the short to 
medium term (<40 years), adding screening could 
more than double the number of cervical cancer cases 
averted in LMICs (vs HPV vaccination alone). In the 
longer term, the models predicted that 93·5 million 
(93·5–95·3) cervical cancer cases will occur in LMICs 
Figure 2: Variability in model predictions of the impact of HPV vaccination and screening strategies
The average age-standardised cervical cancer incidence per 100 000 women-years over time in low-income countries and lower-middle-income countries, 
by World Bank income level (A) and region (B). The solid line represents the median prediction and shaded area represents the minimum and maximum 
predictions of the three models. Vaccination coverage=90% at age 9 years (and at ages 10–14 years in 2020). Vaccine efficacy=100% against HPV types 16, 18, 31, 
33, 45, 52, and 58. Vaccine duration=lifetime. Screening=HPV testing. Screening uptake=45% (2023–29), 70% (2030–44), and 90% (2045 onwards). Screen and 
treat efficacy=100%. Loss to follow-up=10%. Equilibrium occurs 90–100 years after the introduction of HPV vaccination only (and earlier for the screening 
scenarios). HPV=human papillomavirus.
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Figure 3: Global map of cervical cancer elimination in 78 low-income and lower-middle-income countries
Age-standardised incidence of cervical cancer at equilibrium (2100–20), assuming status quo (A), girls-only vaccination (B), and girls-only vaccination and two lifetime 
screens (C). Median prediction from the three models. Vaccination coverage=90% at age 9 years (and at ages 10–14 years in 2020). Vaccine efficacy=100% against 
HPV16, 18, 31, 33, 45, 52, and 58.Vaccine duration=lifetime. Screening=HPV testing. Screening uptake=45% (2023–29), 70% (2030–44), and 90% (2045 onwards). 
Screen and treat efficacy=100%. Loss to follow-up=10%. See videos 1–3 for the global maps of cervical cancer elimination over time and the appendix (p 6) for the 
change in the distribution of the country-specific age-standardised cervical cancer incidence over time. HPV=human papillomavirus.
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between 2020 and 2120 without further scale-up of HPV 
vaccination or cervical screening (ie, the status quo 
scenario). During this period, including girls-only HPV 
vaccination with 90% coverage was predicted to avert 
61·0 million (60·5–63·0) cervical cancer cases; adding 
once-lifetime screening to vaccination was predicted to 
avert an extra 6·8 million (4·3–9·4) cases and adding 
twice-lifetime screening was predicted to avert an extra 
12·1 million (9·5–13·7) cervical cancer cases (figure 5; 
appendix pp 2–4). Overall, an estimated 74·1 million 
(70·4–75·1) cases would be averted by 2120 through 
intensive scale-up of girls-only HPV vaccination with 
twice-lifetime screening. Predictions of the number of 
cervical cancer cases averted over time were similar for 
the three models, at the global and regional levels 
(appendix p 9).
Most cervical cancer cases averted through HPV 
vaccination and screening in LMICs were predicted to be 
among women living in sub-Saharan Africa (figure 5; 
appendix pp 2–4). For example, our models predicted that 
HPV vaccination and twice-lifetime screening will avert 
49·9 million (range 49·5–50·9) cases in sub-Saharan 
Figure 4: Impact of current cervical cancer incidence on elimination predictions
The age-standardised incidence of cervical cancer (A) and relative (B) and absolute (C) reduction in incidence at equilibrium (2100–20) following vaccination and 
screening, as a function of initial age-standardised incidence of cervical cancer for each low-income and lower-middle-income country. Median prediction from the 
three models. Vaccination coverage=90% at age 9 years (and at ages 10–14 years in 2020). Vaccine efficacy=100% against HPV16, 18, 31, 33, 45, 52, and 58. 
Vaccine duration=lifetime. Screening=HPV testing. Screening uptake=45% (2023–29), 70% (2030–44), and 90% (2045 onwards). Screen and treat efficacy=100%. 
Loss to follow-up=10%. HPV=human papillomavirus.
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Africa over the next century, which represents about 
70% of all cases averted in LMICs.
The sensitivity analysis suggests that a small 
reduction in HPV vaccination coverage from 90% 
to 80% would have little impact on the decline in 
cervical cancer incidence in the first 30 years following 
girls-only HPV vaccination (without screening), but 
would lead to slightly higher long-term incidence 
(appendix pp 10–11). Hence, some LMICs that can 
eliminate cervical cancer with 90% vaccination coverage 
(using the threshold of four or fewer cases per 
100 000 women-years) might not with 80% coverage 
(eg, countries with current age-standardised cervical 
cancer incidence of 20–25 cases per 100 000 women-
years). In general, if HPV vaccination coverage was 
high among girls, vaccinating boys was predicted to 
produce very small incremental gains in cervical can-
cer prevention (appendix pp 10–11). For example, the 
CCEMC models predicted that girls-only HPV 
vaccination with 90% coverage would produce the same 
reduction in cervical cancer incidence as vac cinating 
both girls and boys at 80% coverage. Hence, vaccinating 
boys in addition to girls would not be sufficient to help 
countries with the highest age-standardised cervical 
cancer incidence (eg, Uganda) reach the elimination 
threshold of four or fewer cases per 100 000 women-
years. Finally, the models predicted that multi-age 
cohort vaccination up to age 25 years would substan-
tially accelerate the declines in cervical cancer inci-
dence, but would not change cervical cancer incidence 
at equilibrium (appendix pp 10–11). Thus, vaccinating 
older cohorts of girls or women would not ultimately 
change the potential for elimination.
A sensitivity analysis examining the impact of screening 
suggests that although twice-lifetime screening without 
HPV vaccination would substantially reduce cervical 
cancer incidence, the age-standardised cervical cancer 
incidence would remain higher than four cases per 
100 000 women-years in the countries examined (appendix 
pp 10–11). Hence, HPV vaccination is required for most 
LMICs to reach cervical cancer elimination. In the context 
of high-coverage girls-only vaccination, adding a third 
lifetime screen (to HPV vaccination and twice-lifetime 
screening) was predicted to provide very small additional 
gains in cervical cancer prevention, and only slightly 
accelerated time to elimination.
Finally, our sensitivity analysis showed that the 
duration of protection and the number of types included 
in the HPV vaccine can affect whether girls-only HPV 
vaccination with twice-lifetime screening leads to 
cervical cancer elimination (appendix pp 10–11). When 
assuming 20 years of vaccine protection (instead of 
lifelong), the models predicted that the age-standardised 
cervical cancer incidence would be higher than four 
cases per 100 000 women-years in the countries exa-
mined. Thus, a long-term duration of vaccine protection 
(>20 years) is required to reach elimination in LMICs. 
The models predicted that cervical cancer elimination 
might be possible in LMICs with an age-standardised 
incidence of fewer than 25 cases per 100 000 women-
years (eg, Vietnam) by use of a vaccine that includes only 
HPV types 16 and 18. However, for LMICs with the 
highest cervical cancer incidence (eg, Uganda), broad-
spectrum protection against HPV types 16, 18, 31, 33, 45, 
Figure 5: Cervical cancer cases averted
Cumulative cases averted by girls-only vaccination or girls-only vaccination plus screening, and incremental cases 
averted by screening in addition to vaccination over time, for lower-middle-income countries (A), low-income 
countries (B), and by region (C). Median prediction from the three models. Error bars represent the minimum and 
maximum estimates from the three models. Vaccination coverage=90% at age 9 years (and at ages 10–14 years 
in 2020). Vaccine efficacy=100% against HPV types 16, 18, 31, 33, 45, 52, and 58. Vaccine duration=lifetime. 
Screening=HPV testing. Screening uptake=45% (2023–29), 70% (2030–44), and 90% (2045 onwards). Screen and 
treat efficacy=100%. Loss to follow-up=10%. HPV=human papillomavirus.
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52, and 58 was predicted to be required for these 
countries to reach elimination.
Elimination was generally easier to achieve under the 
different scenarios examined in the sensitivity analysis 
with the thresholds of fewer than ten cases per 
100 000 women-years and 85% or greater reduction. The 
models predicted that all vaccination strategies will 
achieve elimination, except for girls-only vaccination 
with 80% coverage. Twice-lifetime screening (without 
vaccination) could also potentially lead to elimination 
with these thresholds in LMICs that have an age-
standardised cervical cancer incidence of less than 
25 cases per 100 000 women-years (eg, Vietnam).
Discussion
Our comparative modelling analysis, which includes 
projections from three independent transmission-
dynamic models, provides consistent results predicting 
that cervical cancer can be eliminated as a public health 
problem by the end of the century, based on WHO’s 
proposed elimination threshold (ie, cervical cancer 
incidence of four or fewer cases per 100 000 women-
years). Our modelling study shows that girls-only HPV 
vaccination would lead to cervical cancer elimination in 
most LMICs, if high coverage is reached (>90% coverage) 
and the vaccine provides long-term protection. However, 
countries with the highest cervical cancer incidence at 
present (>25 cases per 100 000 women-years), more than 
90% of which are in sub-Saharan Africa, would not reach 
elimination by vaccination alone. To achieve cervical 
cancer elimination in all 78 LMICs, our models predict 
that scale-up of both girls-only HPV vaccination and 
twice-lifetime screening is necessary, with 90% HPV 
vaccination coverage, 90% screening uptake, and long-
term protection against HPV types 16, 18, 31, 33, 45, 52, 
and 58. If this global elimination strategy of combined 
intensive scale-up of HPV vaccination and cervical 
screening can be achieved, our results suggest that 
cervical cancer elimination could be achieved in all 
countries by 2100. In doing so, cervical cancer incidence 
would be reduced by 97% and more than 74 million 
cases would be averted over the next century.
In January, 2019, the Executive Board of WHO requested 
the Director-General to lead the development of a draft 
global strategy to accelerate cervical cancer elimination, 
with clear targets for 2030.24 The draft global strategy 
will be presented for consideration at the World Health 
Assembly in May, 2020. The results presented in this 
study were used to help inform the following key 
elements of the global strategy: the cervical cancer 
elimination threshold, the intervention strategies needed 
to achieve global elimination, and the 2030 targets 
towards global elimination.
Elimination of cervical cancer requires a clear and 
commonly agreed upon threshold, under which cervical 
cancer would no longer be considered a public health 
problem.24 Establishment of this threshold thus requires 
a careful and informed process, as it is more complex 
than the definition of elimination (or eradication) of 
an infectious disease, which is simply reduction to 
zero incidence. The proposed threshold of four or fewer 
cases per 100 000 women-years was established on the 
basis of the definition of a rare cancer,44 on the global 
distribution of cervical cancer incidence showing that 
this threshold is currently reached in only a few countries 
(compared with many countries reaching ten or fewer 
cases per 100 000),42 as well as on our modelling results 
(and those of Simms and colleagues34) showing that 
cervical cancer elimination can be achieved in every 
country with this threshold. In this study, we examined 
the consequences of using alternative thresholds (ten or 
fewer cases per 100 000 women-years and ≥85% reduc-
tion), which were proposed during various WHO 
meetings and consultations,24 on the achievability and 
timing of elimination in LMICs for different prevention 
strategies and country characteristics. Our results show 
that intensive scale-up of both HPV vaccination and 
twice-lifetime screening would eliminate cervical cancer 
in all LMICs for all thresholds investigated.
However, the choice of threshold can produce dispa-
rities in the effort required by countries to achieve 
elimination. For example, based on the threshold or 
ten or fewer cases per 100 000 women-years, only 1% of 
LMICs were unable to achieve elimination through HPV 
vaccination alone. By contrast, based on the proposed 
threshold of four or fewer cases per 100 000 women-
years, 40% of LMICs were unable to achieve elimination 
through vaccination alone. These countries have the 
highest burden of cervical cancer (incidence >25 per 
100 000 women-years) and are mostly in sub-Saharan 
Africa. For these countries, up to 90% uptake of twice-
lifetime screening is required, in addition to vaccination, 
to reach the proposed elimination threshold. More 
generally, our results indicate that elimination will be 
hardest to achieve in countries with the highest burden 
of cervical cancer and lowest income level. Considerable 
financial and political international commitment is 
needed so that HPV vaccination and cervical screening 
resources can be prioritised for these countries, not only 
to achieve global elimination but also to reduce the 
enormous disparities in the worldwide cervical cancer 
burden. This is particularly important since current HPV 
vaccination and cervical screening uptake is very low in 
most low-income and sub-Saharan African countries.2–5
Partly based on the CCEMC projections presented here 
and the considerations described above, WHO has 
proposed the following triple-intervention global cervical 
cancer elimination strategy: intensive scale-up of girls-
only HPV vaccination, twice-lifetime screening, and 
treatment of cancer and precancers.24 The 2030 targets for 
this strategy are for 90% of girls to be fully vaccinated, for 
70% of women to be screened at 35 years and 45 years of 
age, and for 90% of women diagnosed with cervical 
precancer or cancer to receive treatment or care. Our 
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findings suggest that to achieve global elimination by the 
end of the century, these targets need to be met in the 
countries with the highest burden of cervical cancer, and 
these countries also need to be supported to scale up 
twice-lifetime screening from 70% to 90% by 2045. 
Although we show that many LMICs could achieve 
elimination with HPV vaccination alone, the triple-
intervention strategy was chosen as the global elimination 
strategy as it would accelerate elimination by 11–31 years 
and prevent an additional 12 million cervical cancer cases 
over the next century (compared with vaccination alone). 
Furthermore, combining cervical screening with HPV 
vaccination has been predicted to be cost-effective across 
several LMICs.20–22 The CCEMC is currently examining 
the incremental cost-effectiveness of the triple-inter-
vention cervical cancer elimination strategy at the global 
level. Importantly, the proposed global cervical cancer 
elimination strategy provides general direction about the 
country-specific strategies that should be used, which 
should be customised to country-specific epidemiological, 
economic, and social contexts. For example, countries 
might want to scale up vaccination and screening at 
different ages than those modelled, because of logistical 
issues or to maximise uptake.
The base-case vaccination-only strategy examined in the 
comparative-model analysis was routine girls-only HPV 
vaccination at age 9 years with a 1-year multi-age cohort 
catch-up for girls aged 10–14 years. This strategy was 
chosen as it is the recommended strategy by the WHO 
Strategic Advisory Group of Experts on Immunization 
(SAGE)41 and a large body of evidence shows that it 
is highly cost-effective in LMICs and high-income 
countries.17,19,31,32 However, given the recent worldwide 
shortage of vaccine supply, SAGE recommended in 
October, 2019, that multi-age cohort catch-up vaccination 
for girls aged 10–14 years should be postponed to alleviate 
the demand for vaccine doses in the coming years. 
The recommended WHO alternative strategies are 
variants of our base-case vaccination-only strategy: rou-
tine vaccination of girls aged 14 years, with a later switch 
to routine vaccination at an earlier age (eg, 9 years); and 
routine vaccination at age 9 years, with an extended 
interval of 3–5 years between doses.45 The recom-
mendations were partly based on results from HPV-
ADVISE showing that these strategies would produce 
similar benefits to girls-only vaccination at age 9 years 
with a 1-year catch-up for girls aged 10–14 years.46 
Implementation of these alternative strategies would 
alleviate vaccine supply to allow sufficient doses for 
all LMICs to reach 90% coverage within the next 
few years.45 Hence, assuming countries follow SAGE 
recom mendations, the HPV vaccine shortage should 
have little long-term impact on our projections of time to 
elimination provided supply constraints are relieved 
over the next decade. In our sensitivity analysis, we 
examined the impact of gender-neutral and multi-age 
cohort vaccination up to 25 years of age on cervical cancer 
incidence over time. Because our models predict that 
90% girls-only vaccination can almost eliminate HPV 
vaccine types, the incremental benefits of vaccinating 
boys on cervical cancer incidence were predicted to be 
small. Multi-age cohort vaccination up to 25 years of age 
was predicted to substantially accelerate elimination and 
avert additional cervical cancer cases but would have no 
effect on whether a country reaches elimination, which 
is only determined by long-term routine vaccination 
coverage. Given their low incremental impact in relation 
to the number of doses required, WHO recommended 
that countries should temporarily postpone the imple-
mentation of gender-neutral and multi-age cohort HPV 
vaccination strategies, to maximise the number of 
countries that can introduce vaccination.45
The two base-case screening strategies examined, 
primary HPV screen-and-treat testing with once-lifetime 
and twice-lifetime screening, were chosen as they are the 
recommended strategies by WHO.40 These screening 
scenarios were meant to represent a wide range of 
validated HPV tests and future screening tests, given 
their high sensitivity and specificity (see Canfell, Kim, 
Brisson and colleagues27 for an in-depth discussion of 
the screening strategies). Our results suggest that 
including screening in addition to HPV vaccination 
would substantially increase the number of cervical 
cancer cases averted and would accelerate elimination, 
mainly by preventing cases in older, unvaccinated 
women. Additionally, cervical cancer elimination can be 
achieved in all but three LMICs (in sub-Saharan Africa) 
with once-lifetime screening and in all LMICs with 
twice-lifetime screening. This is because even if HPV 
vaccination were to eradicate HPV types 16, 18, 31, 33, 45, 
52, and 58, a proportion of LMICs (mainly in sub-Saharan 
Africa) would still have cervical cancer incidence greater 
than the threshold of four cases per 100 000 women-
years; about 10% of cervical cancers are due to HPV types 
that are not in the currently available HPV vaccines10 
and many countries have cervical cancer incidence 
higher than 40 cases per 100 000 women-years.1 For 
these countries, high cervical screening uptake will 
have to be sustained for elimination to be maintained 
(or additional types would have to be included in future 
HPV vaccines). Finally, in the sensitivity analysis, we 
predicted relatively small additional gains in cervical 
cancer prevention by including a third lifetime screen.
Our study has two major strengths. First, we used a 
comparative modelling approach including three models 
that have been extensively peer reviewed and validated 
with post-vaccination surveillance data.30–36 Without har-
monising the model structure or parameters, the three 
models produced very similar results in terms of absolute 
and relative reductions in cervical cancer incidence and 
cancer cases averted over time following HPV vaccination 
and cervical screening by country, income level, and 
region. Our results are consistent in part because the key 
drivers of our predictions (eg, achievability and timing of 
Articles
588 www.thelancet.com   Vol 395   February 22, 2020
elimination) are country-specific baseline cervical cancer 
incidence and percentage of cancers due to the HPV 
vaccine types, which were based on the same data 
sources.1,10 However, the results were not sensitive to the 
main differences between our models, which were the 
sexual behaviour components. At high HPV vaccination 
coverage and vaccine efficacy, our models predicted 
similar dynamics and herd effects across the different 
LMICs, even though sexual behaviour varies substantially. 
Although we could not directly compare our results to 
other HPV transmission-dynamic models in LMICs 
because of the scarcity of such models and their 
incompatibility in intervention scenarios, a previous 
systematic comparison of 16 HPV models in high-
income countries (including the three CCEMC models) 
showed consistent predictions of the population-level 
impact of HPV vaccination when coverage is high.47 
Second, key knowledge users from WHO were involved 
in all aspects of the study, from its design to interpre-
tations of findings. Additionally, the modelling results 
were presented and discussed at multiple WHO advisory 
group and global stakeholder meetings.24,39,48 This process 
has ensured that the study was responsive to the needs 
of global policy decisions and, importantly, that those 
using the findings are aware of both its strengths 
and limitations.
Our study has four main limitations. First, our 
projections are for more than 100 years, a period over 
which substantial demographic and behavioural changes 
and technological development are anticipated that 
can have an impact on cervical cancer incidence.43,49 
Population growth and changes in life expectancy can 
have an important impact on our predictions of cervical 
cancer cases averted. When producing projections with 
low population predictions from the UN,43 we estimated 
that 62 million cervical cancer cases would be averted with 
the triple-intervention global elimination strategy, and 
that 88 million cases would be averted with the UN’s high 
population predictions, versus 74 million cases with base-
case projections (appendix p 12). However, given that the 
definition of elimination is based on age-standardised 
cervical cancer incidence, demographic changes are 
expected to have minimal impact on our predictions of 
the achievability and timing of elimination. Sexual 
behaviour has been changing in many LMICs, from a 
more traditional pattern of sexual behaviour, with a lower 
reported number of lifetime partners and wider age 
gaps between partners, to a more sex-similar pattern of 
behaviour, where both sexes have a similar and higher 
number of partners and narrow age gaps. In these 
countries (mainly in Asia), age-adjusted HPV infection 
and cervical cancer rates might be increasing,49 and thus 
time to elimination might be slightly longer than 
predicted. Technological developments should not have 
major implications for our predictions, as we assumed 
100% vaccine efficacy, high screening test sensitivity and 
specificity, and 100% treatment efficacy. Second, we 
assumed intensive scale-up and 90% uptake of HPV 
vaccination and cervical screening. These assumptions 
are based on data suggesting that worldwide coverage 
of measles, poliomyelitis, hepatitis B, and diphtheria-
tetanus-pertussis vaccines have reached 84–90% (≥90% in 
many LMICs)50 and that more than 90% of women in 
high-income countries are screened for cervical cancer at 
least once in their lifetime.4 If scale-up is slower than 
modelled, this would delay the predicted timing of 
elimination and reduce the number of cancer cases 
averted, but it would not affect whether or not elimination 
can be achieved. Thirdly, our models do not include 
plausible biological interactions between HIV and HPV 
(eg, HPV acquisition and disease progression might 
be increased among people living with HIV).51 By 
not capturing such interactions, our models might 
over estimate the impact of HPV vaccination in high 
HIV prevalence settings (five of 78 LMICs have HIV 
prevalence ≥10%52). Specific prevention strategies might 
be required for people living with HIV to accelerate 
cervical cancer elimination in high HIV prevalence 
settings. Modelling work is ongoing as part of the CCEMC 
to examine these issues. Finally, our country-specific 
cervical cancer incidence data are based on GLOBOCAN 
estimates,42,53 which, where possible, are derived from 
extrapolation of recent trends in incidence obtained from 
national or subnational population-based cancer registries. 
If cervical cancer incidence is under estimated because of 
under reporting in these countries, elimination might take 
longer than predicted. There is an overwhelming need to 
strengthen population-based cancer surveillance in many 
LMICs to improve the accu racy of GLOBOCAN estimates, 
to inform local cancer control strategies, and to monitor 
whether elimination targets are being met.
In conclusion, our comparative modelling analysis 
suggests that cervical cancer elimination as a public health 
problem is possible by the end of the century, resulting in 
a 97% reduction in cervical cancer incidence in LMICs. To 
achieve elimination across all LMICs under the proposed 
threshold (four or fewer cases per 100 000 women-years), 
both high HPV vaccination coverage and screening 
uptake will be necessary, particularly in countries with the 
highest burden. Considerable international commitment 
will be required to achieve WHO’s triple-intervention 
targets, particularly in countries with the highest burden 
of cervical cancer, where scale-up of vaccination and 
screening resources are most urgently needed. Our 
results are being used by WHO to inform its global 
strategy to accelerate cervical cancer elimination, which 
will be presented at the World Health Assembly in 
May, 2020.
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